Ocugen's Stock Pain Is Real, But Its Gene Therapy Pipeline and $112M Cash Cushion Paint a Different Picture
21.05.2026 - 11:31:25 | boerse-global.de
Ocugen shares are in the midst of a brutal selloff — down roughly 24% over recent weeks and trading at just €1.18, a full 46% below the March high of €2.17. The stock now sits well below its 50-day moving average, with the relative strength index at 28, squarely in oversold territory. With annualized volatility hovering near 90%, this is a high-risk name by any measure.
Yet Wall Street analysts remain unshaken. Four experts are nearly unanimous in their buy ratings, setting a median price target of $10. Canaccord Genuity goes further, calling for $12. That implies upside of more than eight times from current levels — a bet on the science rather than the market’s mood.
The source of that optimism is a Phase 2 readout for OCU410, a gene therapy candidate targeting geographic atrophy. At a medium dose, lesion growth slowed by 31% compared with the control group. More than half of patients showed meaningful vision preservation, and no serious adverse events were reported. The company plans to kick off a pivotal Phase 3 trial in the third quarter, with a rolling approval process for another candidate, OCU400, slated to begin this autumn.
Should investors sell immediately? Or is it worth buying Ocugen?
To fund these late-stage ambitions, Ocugen recently strengthened its balance sheet. Mid-May saw the close of a private placement of 6.75% convertible notes due 2034, generating net proceeds of roughly $112.6 million after the underwriters fully exercised their over-allotment option. Cash runway now extends to 2028 — enough to cover the expensive clinical phase ahead.
Part of the haul went straight to liability management: $32.7 million was used to retire existing debt held by Avenue Capital Group. The remainder will fuel pipeline development and general corporate purposes. CEO Shankar Musunuri has stated clearly that the company’s capital position is sufficient to sustain operations for the next two years.
Still, the first-quarter numbers show why investors remain cautious. Revenue came in at $1.53 million, while the net loss widened to $19.18 million. Earnings per share of minus $0.06 narrowly missed the consensus estimate of minus $0.05. For the full year, analysts project revenue of just $3.33 million and a per-share loss of $0.22 — a reflection of the early developmental stage.
On May 26, Ocugen will present further updates on its gene therapy platform at an industry forum. Between the oversold stock, the supportive analyst consensus, and a pipeline that appears to be hitting its clinical marks, the ingredients for a rebound are there — but execution, not financing, will ultimately decide whether the stock climbs out of its current trough.
Ad
Ocugen Stock: New Analysis - 21 May
Fresh Ocugen information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
